XBI
State Street SPDR S&P Biotech ETF
SPDR S&P Biotech ETF seeks to replicate the performance of the S&P Biotechnology Select Industry Index, an equal-weighed index. The Index tracks all the US common stocks listed on the NYSE, Ame
US
EQUITY
Rules-Based
MANAGEMENT STYLE
$ 11.6 B
ASSETS UNDER MGMT
35 bp
EXPENSES
Fund Basics
| Inception date | Jan 31, 2006 |
| Regulation | Open-Ended Fund |
| Fund Website | link... |
| Distributions | Quarterly |
| Currency | USD |
| Holdings Transparency | Full |
| Derivatives-based | No |
| Options available | Yes |
| Currency hedged | No |
| Fund of funds | No |
Top 10 Holdings
Complete list +
| MODERNA, INC. | 2.8 % |
| TWIST BIOSCIENCE CORP. | 1.9 % |
| ORUKA THERAPEUTICS INC | 1.5 % |
| APOGEE THERAPEUTICS, INC. | 1.5 % |
| PRAXIS PRECISION MEDICINES I | 1.4 % |
| HALOZYME THERAPEUTICS INC | 1.4 % |
| NATERA INC | 1.4 % |
| KYMERA THERAPEUTICS, INC. | 1.4 % |
| PROTAGONIST THERAPEUTICS, INC. | 1.3 % |
| DIANTHUS THERAPEUTICS INC | 1.3 % |
Constituent Breakdown
| Number of holdings | 138 |
| Herfindahl-Hirschman Index | 95 |
| Wgt avg mkt cap (mns) | $18,552 |
| Large cap (>$10bn) | 27.0% |
| Mid cap ($2-10bn) | 50.2% |
| Small cap (<$2bn) | 17.8% |
| Developed mkts. | 96.1% |
| Emerging mkts. | 0.0% |
Sector Breakdown
Country Exposure
 |
UNITED STATES | 91.5 % |
 |
BRITAIN | 1.2 % |
 |
IRELAND | 1.1 % |
 |
SWITZERLAND | 1.1 % |
 |
NETHERLANDS | 1.1 % |
Historical Performance
Standardized Performance (as of 08/31/2026)
| YTD | 1 YR | 2 YR | 3 YR | 5 YR | 10 YR | 20 YR | Incep. | |
|---|---|---|---|---|---|---|---|---|
| Price Returns | 33.3% | 80.9% | 26.7% | 27.1% | 4.1% | 10.5% | 12.5% | 11.8% |
| Dividend Yield | 0.1% | 0.8% | 0.3% | 0.3% | 0.1% | 0.2% | 0.3% | 0.3% |
| Total Returns | 33.4% | 81.7% | 27.0% | 27.3% | 4.2% | 10.6% | 12.8% | 12.1% | Ann. Volatility | 30.5% | 28.1% | 27.8% | 28.0% | 32.4% | 32.0% | 30.8% | 30.6% |
Market Correlations
| versus... | Beta | R-squared |
| S&P 500 | 1.03 | 22% |
| MSCI EAFE | 0.91 | 25% |
| MSCI Emg Mkts | 0.48 | 18% |
Liquidity Measures
| Avg. volume (000) | 8,030 |
| ADV traded (mns) | $1,315 |
| Turnover | 11.3% |
| Avg. Bid/Ask (% of price) | 0.01% |
Technical Indicators
| 30d moving avg. (EMA) | $153.00 |
| Relative strength (RSI) | 58 |
| MACD/Signal | 1.94/1.49 |
| Bollinger Bands (Upper/Lower) | $160.47/$145.62 |
| Short interest (% of AUM) | 112.1% |
Distributions
Top Ten Comparable ETFs only shown here. For an extended list become an Individual or Professional subscriber. Start your FREE trial
Comparable ETFs Based on Overlap
| Ticker | Fund Name | Overlap vs. XBI |
Expenses vs. XBI |
ALTAR Score™ vs. XBI |
|---|---|---|---|---|
| BBP | Virtus LifeSci Biotech Products ETF | 41.5% | +44 bp | -3.2% |
| IBBQ | Invesco Nasdaq Biotechnology ETF | 40.9% | -16 bp | +0.5% |
| IBB | iShares Biotechnology ETF | 40.7% | +10 bp | -0.3% |
| WDNA | WisdomTree BioRevolution Fund | 34.4% | +10 bp | -2.1% |
| BBC | Virtus LifeSci Biotech Clinical Trials ETF | 34.0% | +44 bp | +0.2% |
| PTH | Invesco Dorsey Wright Healthcare Momentum ETF | 31.1% | +25 bp | -0.9% |
| SBIO | ALPS Medical Breakthroughs ETF | 25.7% | +15 bp | +0.2% |
| GNMX | Corgi Genomics & Precision Medicine ETF | 25.7% | 0 bp | -2.9% |
| FTXH | First Trust Nasdaq Pharmaceuticals ETF | 25.6% | +25 bp | +6.7% |
| CANC | Tema Oncology ETF | 24.9% | +40 bp | -1.6% |
Risk and Returns: XBI vs. Comps (1 YR)
Notes: Top 10 overlapping ETFs. Funds with insufficient history not shown. Some funds may overlap. Hover over data point for ticker symbol.
Content on this tab for Individual & Professional subscribers only. Start your FREE trial
Results & Estimates (USD)
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | ||
|---|---|---|---|---|---|---|---|---|---|
| Sales per share | -- | -- | -- | -- | -- | -- | -- | ||
| change (%) | -- | -- | -- | -- | -- | -- | -- | ||
| Earnings per share | -- | -- | -- | -- | -- | -- | -- | ||
| change (%) | -- | -- | -- | -- | -- | -- | -- | ||
| Dividends per share | -- | -- | -- | -- | -- | -- | -- | ||
| change (%) | -- | -- | -- | -- | -- | -- | -- | ||
| Book value per share | -- | -- | -- | -- | -- | -- | -- | ||
| change (%) | -- | -- | -- | -- | -- | -- | -- |
Return on Equity
Net Margins
Content on this tab for Individual & Professional subscribers only. Start your FREE trial
Valuation Metrics
| Fwd Est | 2025 | 2026 | 2027 | |
| Price-to-sales | --x | --x | --x | --x |
| Price-to-earnings | --x | --x | --x | --x |
| Price-to-cash flow | --x | --x | --x | --x |
| Price-to-growth | --x | --x | --x | --x |
| Price-to-book value | --x | --x | --x | --x |
| Yield | --% | --% | --x | --% |
Based on closing prices from 9/5/2026
Peer Group Comparison
Sample data. Subscribe for access.
Historical Valuation Trends Sample data. Subscribe for access.
Notes: Based on adjusted historical results for current fund constituents. May differ from results achieved by past fund constituents. Max P/E of 100x.
Some content on this tab for Individual & Professional subscribers only. Start your FREE trial
ETF Research Center Rating
-0.2%
ALTAR SCORE™
1st
PERCENTILE
AVOID
ETFRC RATING
There are 1,408 funds in the US Equity category with an average
ALTAR Score™ of 5.2% and a standard deviation
of 2.0%. XBI's ALTAR Score™ is approximately -2.8 standard
deviations above the category average. This places XBI in the 1st percentile
among funds in the category.
Sell-Side Consensus
$169.03
PRICE TARGET
+3.2%
UPSIDE